Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mothaffar F Rimawi

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Cancers|April 3, 2021
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Mario Giuliano, Fabiola Giudici, et al.
NPJ Breast Cancer|May 28, 2021
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft modelsJamunarani Veeraraghavan, Carolina Gutierrez, Vidyalakshmi Sethunath, et al.
Cell Reports|July 19, 2023
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancerXiaoyong Fu, Resel Pereira, Chia-Chia Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2015
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)Nancy U Lin, Hao Guo, Jeffrey T Yap, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2018
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR TrialIrene L Wapnir, Karen N Price, Stewart J Anderson, et al.
The Lancet. Oncology|January 21, 2014
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trialStefan Aebi, Shari Gelber, Stewart J Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancerLisa A Carey, Hope S Rugo, P Kelly Marcom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2015
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 TherapyMario Giuliano, Huizhong Hu, Yen-Chao Wang, et al.
Journal of the National Cancer Institute|October 11, 2025
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2019
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancerXiaoyong Fu, Resel Pereira, Carmine De Angelis, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Cancers|April 3, 2021
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Mario Giuliano, Fabiola Giudici, et al.
NPJ Breast Cancer|May 28, 2021
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft modelsJamunarani Veeraraghavan, Carolina Gutierrez, Vidyalakshmi Sethunath, et al.
Cell Reports|July 19, 2023
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancerXiaoyong Fu, Resel Pereira, Chia-Chia Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2015
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)Nancy U Lin, Hao Guo, Jeffrey T Yap, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2018
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR TrialIrene L Wapnir, Karen N Price, Stewart J Anderson, et al.
The Lancet. Oncology|January 21, 2014
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trialStefan Aebi, Shari Gelber, Stewart J Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancerLisa A Carey, Hope S Rugo, P Kelly Marcom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2015
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 TherapyMario Giuliano, Huizhong Hu, Yen-Chao Wang, et al.
Journal of the National Cancer Institute|October 11, 2025
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2019
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancerXiaoyong Fu, Resel Pereira, Carmine De Angelis, et al.
Pageof 8